# Shionogi clinical trials: 105 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 105 trials with Shionogi as lead sponsor, 10 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Shionogi: 105 rows for $5.25, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/shionogi

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 105
- Recruiting or not yet: 10
- Read on: November 19, 2026

## Trials

The 25 newest of 105, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 5, 2026 | NCT07857837 | Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls | Shionogi | Phase 1 | Not yet recruiting | Renal Impairment | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857837) |
| August 26, 2026 | NCT07787650 | A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD) | Shionogi | Phase 1 | Not yet recruiting | Pompe Disease | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07787650) |
| August 6, 2026 | NCT07750990 | An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD) | Shionogi | Phase 2 | Not yet recruiting | Pompe Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750990) |
| August 5, 2026 | NCT07746544 | Study of Secutrelvir in Participants With COVID-19 | Shionogi | Phase 3 | Recruiting | COVID-19 | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746544) |
| August 4, 2026 | NCT07743580 | A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease | Shionogi | Phase 3 | Recruiting | SARS-CoV-2 | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743580) |
| October 20, 2025 | NCT07217886 | A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls | Shionogi | Phase 1 | Completed | Renal Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217886) |
| October 9, 2025 | NCT07214571 | A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to... | Shionogi | Phase 2 | Recruiting | Respiratory Syncytial Virus Infections | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214571) |
| August 14, 2025 | NCT07123155 | Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | Shionogi | Phase 2 | Recruiting | Pompe Disease | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07123155) |
| July 30, 2025 | NCT07093580 | Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants | Shionogi | Phase 1 | Recruiting | Healthy Participants | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07093580) |
| June 12, 2025 | NCT07018492 | Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls | Shionogi | Phase 1 | Completed | Hepatic Impairment | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07018492) |
| June 10, 2025 | NCT07012005 | Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls | Shionogi | Phase 1 | Completed | Renal Impairment | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07012005) |
| June 10, 2025 | NCT07011992 | A Study to Assess the Effects of BPN14770 on Rosuvastatin | Shionogi | Phase 1 | Completed | Healthy Participants | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011992) |
| April 15, 2025 | NCT06928051 | A Study of S-892216 in Participants With COVID-19 | Shionogi | Phase 2 | Completed | COVID-19 | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06928051) |
| January 15, 2025 | NCT06776432 | Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea | Shionogi | Phase 2 | Active not recruiting | Sleep Apnea | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06776432) |
| January 15, 2025 | NCT06775730 | A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants | Shionogi | Phase 1 | Completed | Healthy Adult Female Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06775730) |
| December 27, 2024 | NCT06751017 | A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants | Shionogi | Phase 1 | Completed | COVID-19 | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06751017) |
| December 24, 2024 | NCT06746051 | A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants | Shionogi | Observational | Completed | RSV Infections | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06746051) |
| December 9, 2024 | NCT06724978 | A Study of S-740792 in Healthy Adult Study Participants | Shionogi | Phase 1 | Completed | Healthy Participants | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06724978) |
| December 5, 2024 | NCT06717438 | Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome \[JS\]) | Shionogi | Phase 2 | Active not recruiting | Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06717438) |
| February 21, 2024 | NCT06270511 | A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants | Shionogi | Phase 1 | Completed | Healthy Volunteers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06270511) |
| October 30, 2023 | NCT06106334 | Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants | Shionogi | Phase 1 | Completed | Obesity, Healthy Volunteers | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06106334) |
| October 17, 2023 | NCT06086626 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants | Shionogi | Phase 2 | Completed | Gram-Negative Bacterial Infections | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06086626) |
| July 20, 2023 | NCT05953480 | A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke | Shionogi | Phase 2 | Completed | Acute Ischemic Stroke | 680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05953480) |
| June 29, 2023 | NCT05925114 | Safety and Efficacy Study of S-309309 in Obese Adults | Shionogi | Phase 2 | Completed | Obesity | 365 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05925114) |
| June 9, 2023 | NCT05897541 | Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection | Shionogi | Phase 3 | Completed | SARS-CoV-2 Infection | 3,701 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05897541) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 34 |
| Phase 1/2 | 4 |
| Phase 2 | 28 |
| Phase 3 | 33 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 84 |
| Terminated | 8 |
| Recruiting | 7 |
| Not yet recruiting | 3 |
| Active not recruiting | 2 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Obesity | 7 |
| COVID-19 | 7 |
| Opioid-Induced Constipation | 6 |
| Amyotrophic Lateral Sclerosis | 6 |
| Atrophy | 6 |
| Vaginal Diseases | 6 |
| Renal Insufficiency | 5 |
| Thrombocytopenia | 3 |
| Ischemic Stroke | 3 |
| Glycogen Storage Disease Type II | 3 |
| Rare Diseases | 3 |
| Glycogen Storage Disease | 3 |
| Healthcare-Associated Pneumonia | 3 |
| Sepsis | 3 |
| Pneumonia, Ventilator-Associated | 3 |
| Gram-Negative Bacterial Infections | 3 |
| Lung Neoplasms | 2 |
| Neovascularization, Pathologic | 2 |
| Purpura, Thrombocytopenic, Idiopathic | 2 |
| Blood Platelet Disorders | 2 |
| Hematologic Diseases | 2 |
| Purpura, Thrombotic Thrombocytopenic | 2 |
| Respiratory Syncytial Virus Infections | 2 |
| Depressive Disorder | 2 |
| Influenza, Human | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Brewing supply stores in the United States](https://specstream.ai/data/businesses/brewing-supply-stores/united-states)
- [Neuropathology practices in the United States](https://specstream.ai/data/businesses/neuropathology-practices/united-states)
- [Bed and breakfasts in the United States](https://specstream.ai/data/businesses/bed-and-breakfasts/united-states)
- [Middle schools in the United States](https://specstream.ai/data/businesses/middle-schools/united-states)
- [Backflow companies in the United States](https://specstream.ai/data/businesses/backflow-companies/united-states)
- [Medical billing companies in the United States](https://specstream.ai/data/businesses/medical-billing-companies/united-states)
